Yahoo Finance BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know
BioNTech SE Sponsored ADR (BNTX) closed at $132.08 in the latest trading session, marking a +1.88% move from the prior day. This change outpaced the S&P 500's 0.89% gain on the day. At the same time, the Dow added 1.2%, and the tech-heavy Nasdaq lost 0.68%.
Prior to today's trading, shares of the company had lost 6.48% over the past month. This has lagged the Medical sector's loss of 4.48% and the S&P 500's loss of 3.9% in that time.
Investors will be hoping for strength from BioNTech SE Sponsored ADR as it approaches its next earnings release, which is expected to be March 27, 2023. On that day, BioNTech SE Sponsored ADR is projected to report earnings of $8.68 per share, which would represent a year-over-year decline of 37.69%. Meanwhile, our latest consensus estimate is calling for revenue of $4.31 billion, down 31.95% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for BioNTech SE Sponsored ADR. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. BioNTech SE Sponsored ADR is currently a Zacks Rank #5 (Strong Sell).
Investors should also note BioNTech SE Sponsored ADR's current valuation metrics, including its Forward P/E ratio of 10.53. This valuation marks a discount compared to its industry's average Forward P/E of 18.24.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
